Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations.
Although research and development of new penicillins have declined, penicillins continue to be essential antibiotics for the treatment and prophylaxis of infectious diseases. The most recent additions are the ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. This article reviews the spectrum of activity, toxicity, pharmacokinetics, and clinical uses of the ureidopenicillins, and the beta-lactam/beta-lactamase inhibitor combination agents.
Bush
L M
LM
Division of Infectious Diseases, John F. Kennedy Memorial Medical Center, West Palm Beach, Florida, USA.
Johnson
C C
CC
D000818:Animals; D000900:Anti-Bacterial Agents; D001424:Bacterial Infections / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D010403:Penicillin Resistance; D010406:Penicillins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases